Ascendis observational study for ACH is ready to start

ACHieve is a long-term, multi-center, longitudinal, observational study

Read more ...

Ascendis TransCon CNP receives Orphan Drug Designation

On the Feb 28th  2019, Ascendis announced that the innovative medicine

Read more ...

A new word ASDD

THE MOST DIFFICULT WORD

Read more ...

2nd Meeting on Rare Bone Diseases in Coimbra

More than 80 healthcare professionals, hospital administrator, industry, students

Read more ...

Therachon´s Observational study open for recruitment

TA46-002 is the Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia

Read more ...

Phase 1 data for TransCon CNP

Ascendis Pharma presented on the 28th November 2018,
Read more ...

New data on Vosorite for achondroplasia

BioMarin Research & Development day 2018, was presented 

Read more ...

4th Conference on European Reference Networks - ERNs in action

This ERNs conference

Read more ...

ALPE at BioMarin European Patient Advocacy Forum 2018

On the 17th November 2018, Carmen Alonso represented ALPE

Read more ...